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Abstract   24 
Multiple differentially methylated sites and regions associated with adiposity have 25 
now been identified in large-scale cross sectional studies. We tested for replication of 26 
associations between previously identified CpG sites at HIF3A and adiposity in 27 
~1,000 mother-offspring pairs from the Avon Longitudinal Study of Parents and 28 
Children. Availability of methylation and adiposity measures at multiple time points, 29 
as well as genetic data, allowed us to assess the temporal associations between 30 
adiposity and methylation and to make inferences regarding causality and 31 
directionality.  32 
 33 
Overall, our results were discordant with those expected if HIF3A methylation has a 34 
causal effect on BMI and provided more evidence for causality in the reverse 35 
direction i.e. an effect of BMI on HIF3A methylation. These results are based on 36 
robust evidence from longitudinal analyses and were also partially supported by 37 
Mendelian randomization analysis, although this latter analysis was underpowered to 38 
detect a causal effect of BMI on HIF3A methylation.  Our results also highlight an 39 
apparent long-lasting inter-generational influence of maternal BMI on offspring 40 
methylation at this locus, which may confound associations between own adiposity 41 
and HIF3A methylation. Further work is required to replicate and uncover the 42 
mechanisms underlying both the direct and inter-generational effect of adiposity on 43 
DNA methylation.   44 
 45 





Introduction  49 
The notion that epigenetic processes are linked to variation in adiposity is well 50 
established.(1) Genome-wide quantification of site-specific DNA methylation has led 51 
to the identification and validation of multiple adiposity-associated differentially 52 
methylated sites and regions.(2-8)  53 
 54 
A large-scale epigenome-wide association study (EWAS) of body mass index (BMI), 55 
undertaken using the Illumina Infinium HumanMethylation450 BeadChip array, 56 
found robust associations between BMI and DNA methylation at three neighbouring 57 
probes in intron 1 of HIF3A which were confirmed in two additional independent 58 
cohorts.(6) Since then, the site locus has also been associated with adiposity in four 59 
further studies.(7-10)  Furthermore, HIF3A methylation has been found to be 60 
associated with weight but not height, and methylation at this locus in adipose tissue 61 
has been found to be strongly associated with BMI (6; 7) indicating that methylation 62 
at this locus might be related to some component of adiposity. 63 
 64 
HIF3A and other hypoxia inducible transcription factors (HIF) regulate cellular and 65 
vascular responses to decreased levels of oxygen, and studies in mice suggest they 66 
may play key roles in metabolism, energy expenditure and obesity.(11-14) This lends 67 
support for a role of this gene in the development of obesity and its consequent co-68 
morbidities. However, it is also possible that greater BMI induces changes in HIF3A 69 
methylation as the direction of the effect is difficult to discern in these cross-sectional 70 




Further research is required to determine the directionality of the association and 73 
strengthen inference regarding causality. A large-scale longitudinal design is 74 
warranted to investigate the temporal relationship between baseline adiposity and 75 
follow-up methylation, and vice versa.(15-17)  76 
 77 
Mendelian randomization uses genetic variants as instrumental variables (IVs) to 78 
investigate the causal relationship between an exposure and outcome of interest.(18-79 
21)  The assumptions of this approach are that the instrumental variable is: robustly 80 
related to the exposure; related to the outcome only through its robust association with 81 
the exposure of interest; and not related to confounding factors for the exposure-82 
outcome association and not influenced by the development of the outcome. If these 83 
assumptions are true then any association observed between the IV and outcome is 84 
best explained by a true causal effect of the exposure on the outcome.(22) It has been 85 
shown that genetic variants are not likely to be related to confounding factors that 86 
explain non-genetic associations and are unaffected by disease,  (23) and therefore 87 
may be used to strengthen causal inference.  88 
 89 
In the context of methylation, Mendelian randomization may be facilitated by the 90 
strong cis-effects which allow the isolation of specific loci influencing methylation 91 
(24) and has been applied elsewhere to assess causal effects.(25; 26) In the study that 92 
identified differential methylation at HIF3A,(6) cis-genetic variants robustly 93 
associated with DNA methylation at this locus were used as causal anchors in a 94 
pseudo Mendelian randomization approach to assert no causal effect of methylation at 95 
HIF3A on adiposity. However, no attempt was made to investigate causality in the 96 
reverse direction i.e. the causal effect of adiposity on HIF3A methylation. 97 
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Bidirectional Mendelian randomization may be used to elucidate the causal direction 98 
between HIF3A and adiposity, using valid IVs for each trait.(21; 27; 28)   99 
 100 
Investigating a possible inter-generational intra-uterine effect of maternal BMI on 101 
offspring methylation could further strengthen causal inference since it is plausible 102 
that maternal BMI could influence offspring methylation through intra-uterine effects 103 
independent of offspring’s own BMI.(29) Indeed, a recent study postulated and found 104 
some evidence for a confounding effect of the prenatal environment on the 105 
association between adiposity and HIF3A methylation through an assessment of birth 106 
weight.(9) Alternatively, confounding by familial socio-economic and lifestyle 107 
characteristics may explain the observed associations between adiposity on HIF3A  108 
methylation and this was not fully assessed in the previous study.(6)  109 
 110 
We aimed to investigate associations between methylation at HIF3A and BMI at 111 
different ages using data from the Avon Longitudinal Study of Parents and Children 112 
as part of the Accessible Resource for Integrated Epigenomics Studies (ARIES) 113 
project. We first estimated effect sizes for the three previously identified probes in 114 
HIF3A, with and without adjustment for a number of potential confounding factors. 115 
Given evidence of an association between HIF3A methylation and components of 116 
adiposity specifically, we also investigated associations between methylation at 117 
HIF3A and fat mass index (FMI).(6; 7) To further investigate the dominant direction 118 
of causality in any observed associations we undertook the following additional 119 
analyses: a) investigating longitudinal associations between BMI and methylation b) 120 
performing bidirectional Mendelian randomization analysis c) determining whether 121 
there is an inter-generational effect of parental BMI on offspring methylation, either 122 
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through an intra-uterine effect of maternal BMI or a postnatal effect of 123 
paternal/maternal BMI through shared familial lifestyle or genetic factors (Figure 1).  124 
The results of the various analyses which would be expected under the different 125 
hypotheses being tested are outlined in Supplementary Table 1.   126 
 127 
Research Design and Methods  128 
Participants  129 
ALSPAC is a large, prospective birth cohort study based in the South West of 130 
England. 14,541 pregnant women resident in Avon, UK with expected dates of 131 
delivery 1st April 1991 to 31st December 1992 were recruited and detailed information 132 
has been collected on these women and their offspring at regular intervals.(30; 31) 133 
The study website contains details of all the data that is available through a fully 134 
searchable data dictionary (http://www.bris.ac.uk/alspac/researchers/data-access/data-135 
dictionary/).  136 
   137 
As part of the ARIES (Accessible Resource for Integrated Epigenomic Studies) 138 
project,(32) the Illumina Infinium® HumanMethylation450K (HM450) BeadChip 139 
(Illumina Inc., CA, USA)(33) has been used to generate epigenetic data on 1,018 140 
mother-offspring pairs in the ALSPAC cohort (v1. Data release 2014). A web portal 141 
has been constructed to allow openly accessible browsing of aggregate ARIES DNA 142 
methylation data (ARIES-Explorer, http://www.ariesepigenomics.org.uk/).  143 
 144 
The ARIES participants were selected based on availability of DNA samples at two 145 
time points for the mother (antenatal and at follow-up when the offspring were 146 
adolescents) and three time points for the offspring (neonatal, childhood (mean age 147 
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7.5 years) and adolescence (mean age 17.1 years)). We focused our analyses on 148 
offspring in the ARIES study who have more detailed longitudinal and parental 149 
exposure data available. Therefore, this project uses methylation data from the three 150 
time points in the offspring. A detailed description of the data available in ARIES is 151 
available in a Data Resource Profile for the study.(32)  152 
 153 
Written informed consent has been obtained from all ALSPAC participants. Ethical 154 
approval for the study was obtained from the ALSPAC Ethics and Law Committee 155 
and the Local Research Ethics Committees.  156 
 157 
Methylation assay – laboratory methods, quality control and pre-processing  158 
We examined DNA methylation in relation to body mass index using methylation 159 
data from the Infinium HM450 BeadChip.(33) The Infinium HM450 Beadchip assay 160 
detects the proportion of molecules methylated at each CpG site on the array. For the 161 
samples, the methylation level at each CpG site was calculated as a beta value (β), 162 
which is the ratio of the methylated probe intensity and the overall intensity and 163 
ranges from 0 (no cytosine methylation) to 1 (complete cytosine methylation).(34; 35) 164 
All analyses of DNA methylation used these beta values. 165 
 166 
Cord blood and peripheral blood samples (whole blood, buffy coats or blood spots) 167 
were collected according to standard procedures and the DNA methylation wet-lab 168 
and pre-processing analyses were performed as part of the ARIES project, as 169 
previously described.(32) In brief, samples from all time points in ARIES were 170 
distributed across slides using a semi-random approach to minimise the possibility of 171 
confounding by batch effects. The main batch variable was found to be the bisulphite 172 
8 
 
conversion plate number. Samples failing QC (average probe p-value >= 0.01, those 173 
with sex or genotype mismatches) were excluded from further analysis and scheduled 174 
for repeat assay and probes that contained <95% of signals detectable above 175 
background signal (detection p-value <0.01) were excluded from analysis. 176 
Methylation data were pre-processed using in R (version 3.0.1), with background 177 
correction and subset quantile normalisation performed using the pipeline described 178 
by Touleimat and Tost.(36) In the offspring, 914 samples at birth, 973 samples at 179 
follow-up in childhood and 974 samples at follow-up in adolescence passed the QC. 180 
 181 
Anthropometry  182 
In childhood (mean age 7.5) and adolescence (mean age 17.1), offspring attended 183 
follow-up clinics where weight and height were measured with the participant in light 184 
clothing and without shoes. Weight was measured to the nearest 0.1kg with Tanita 185 
scales and height to the nearest 0.1cm using a Harpenden stadiometer. Body mass 186 
index (kg/m2) was then calculated. At the adolescent clinic, fat mass (kg) and lean 187 
mass (kg) were also assessed by Lunar Prodigy dual energy x-ray absorptiometry 188 
(DXA) scanner (GE Medical Systems Lunar, Madison, WI).  The scans were visually 189 
inspected and realigned where necessary. Once complete, the tester examined the scan 190 
to ensure its quality and if necessary repeated the scan. The fat mass index (FMI; 191 
kg/m2) was calculated.  192 
 193 
After recruitment, mothers were asked to report their height and pre-pregnancy 194 
weight in a questionnaire administered at 12 weeks gestation, which were then used to 195 
calculate pre-pregnancy maternal BMI. Reported weight was highly correlated with 196 
the first antenatal clinic measure of weight (Pearson’s correlation coefficient 0.95). 197 
9 
 
Partners reported their own heights and weights in questionnaires at 12 weeks 198 
gestation, which were used to determine paternal BMI. For this study, data for 199 
partners who were not confirmed as being the biological father of the child by the 200 
mothers’ report were excluded.  201 
 202 
Other variables 203 
Age, sex, birth weight, gestational age, maternal education, household social class, 204 
maternal smoking and alcohol consumption in pregnancy and own smoking and 205 
alcohol were also considered potential confounders.  Sex, gestational age and infant 206 
birth weight were recorded in the delivery room and abstracted from obstetric records 207 
and/or birth notifications. Gestational age was based on the date of the mother’s last 208 
menstrual period, clinical records or ultrasounds. Based on questionnaire responses in 209 
pregnancy, the highest occupation of the mother or their partner was used to define 210 
family social class as either manual or non-manual (using the 1991 British Office of 211 
Population and Census Statistics (OPCS) classification). Highest educational 212 
qualification for the mother was collapsed into whether they had achieved a university 213 
degree or not. Mothers were asked about their smoking during pregnancy and these 214 
data were used to generate a binary variable of any smoking during pregnancy. In 215 
addition, mothers were asked whether they had drunk any alcohol during the first 216 
trimester and these data were used to generate a binary variable: never or ever drank 217 
alcohol during the first trimester. Offspring smoking was obtained from a 218 
questionnaire administered at the clinic when DNA was extracted for methylation at 219 
age 15-17 years, and this was categorised into never/less than weekly, weekly and 220 
daily. Adolescent alcohol intake was obtained from the same questionnaires and 221 





ALSPAC offspring were genotyped using the Illumina HumanHap550 quad genome-225 
wide SNP genotyping platform (Illumina Inc., San Diego, CA, USA) by the 226 
Wellcome Trust Sanger Institute (Cambridge, UK) and the Laboratory Corporation of 227 
America (Burlington, NC, US), with support from 23andMe. ALSPAC mothers were 228 
genotyped on the Illumina 660K quad chip at the Centre National de Genotypage, 229 
Paris. DNA extraction, quality control, SNP genotyping and imputation were carried 230 
out separately in the ALSPAC mothers and offspring and have been described in 231 
detail elsewhere.(37; 38)   232 
 233 
Statistical analysis  234 
Cross-sectional analysis  235 
We performed multivariable regression analysis of log-transformed BMI with 236 
concurrently measured methylation level (beta values) at each of the 3 CpG sites in 237 
HIF3A identified (6), in both mothers and offspring in ARIES. Main models were 238 
adjusted for age, sex and bisulphite conversion batch in the analyses of offspring 239 
childhood BMI, and age, sex, smoking status and bisulphite conversion batch in the 240 
analyses of offspring adolescent BMI and maternal BMI. All covariates, including 241 
bisulphite conversion batch, were included as fixed effects. BMI was treated as the 242 
outcome variable by Dick et al. and so we present coefficients as percentage change 243 
per 0.1 increase in methylation so as to be able to compare the magnitude of the 244 
observational estimates directly with those reported (6). DXA-measured fat mass 245 
index (FMI) was also investigated as the outcome variable in a secondary analysis of 246 




Secondary models were adjusted for age, sex, bisuphite conversion batch, birth 249 
weight, gestational age, maternal education, household social class, maternal smoking 250 
and alcohol consumption in pregnancy and own smoking and alcohol . In addition, it 251 
has been demonstrated that differences in methylation can arise as a result of 252 
variability of cell composition in whole blood.(39) In order to ensure that the results 253 
are not influenced by variation in cell type fraction between samples, we estimated 254 
the fraction of CD8+T, CD4+T, NK and B cells, monocytes and granulocytes in the 255 
samples using the estimateCellCounts function in the minfi Bioconductor package 256 
implemented in R.(40) (41) This approach uses as a reference a dataset presented by 257 
Reinius and colleagues which identified differentially methylated regions which could 258 
discriminate cell types in flow-sorted leukocytes from six adult samples. (39) 259 
Analyses were repeated adjusting for cell composition by including each blood cell 260 
fraction as a covariate in the multivariable linear regression.  261 
Additional analyses 262 
To further investigate the dominant direction of causality in any observed associations 263 
we undertook the following additional analyses (Figure 1):  264 
 265 
Longitudinal analysis  266 
Multiple linear regression models were next used to establish the association of 267 
methylation with future adiposity and of adiposity with future methylation in the 268 
offspring, with adjustments made for sex, age and batch, and baseline adiposity or 269 
methylation respectively. Specifically, BMI in adolescence was regressed on 270 
childhood methylation, and methylation in adolescence on childhood BMI. Childhood 271 
methylation was also regressed on birth weight, and childhood BMI on cord blood 272 
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methylation at birth. Secondary models were adjusted for age, sex, batch, baseline 273 
adiposity or methylation, birth weight (where birth weight or methylation at birth was 274 
not the outcome or main exposure), gestational age, maternal education, household 275 
social class, maternal smoking and alcohol consumption in pregnancy and own 276 
smoking and alcohol.  277 
 278 
Mendelian randomization analysis 279 
It is now well established that genetic factors regulate variation in methylation (42) 280 
and two single nucleotide polymorphisms (SNPs), rs8102595 and rs3826795, were 281 
found to have strong cis-effects on methylation at HIF3A.(6) These same SNPs were 282 
not associated with BMI in either the previous study cohorts or in a large-scale meta-283 
analysis of genome-wide association studies (GWAS) for BMI,(43) implying that 284 
increasing methylation at the HIF3A CpG sites does not have a causal effect on BMI. 285 
We aimed to perform formal Mendelian randomization analysis to establish a causal 286 
effect of methylation at HIF3A on BMI using these previously identified cis-SNPs 287 
combined in a weighted allele score, using the weights from a meta-analysis of the 288 
discovery and replication cohorts in Dick et al (6) as a proxy for methylation levels. 289 
 290 
We also performed reciprocal Mendelian randomization analysis to investigate 291 
whether there was evidence of a causal effect of BMI on HIF3A methylation using 292 
genetic variants found to be robustly associated with BMI in large-scale GWAS.(43; 293 
44) For this, a weighted allele score was created from 97 SNPs that have been shown 294 
to be reliably associated with BMI (44) and was used as a genetic instrument for 295 
adiposity. The dose of the effect allele at each locus was weighted by the effect size of 296 
the variant in this independent meta-analysis and these doses were summed to reflect 297 
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the average number of BMI-increasing alleles carried by an individual. Analyses were 298 
performed using a standardised allele score.    299 
 300 
For the Mendelian randomization analyses we used the approach of 301 
“triangulation”.(45-47). This approach involves a comparison of the observed 302 
association between the instrument and the outcome with the association which would 303 
be expected if the observed exposure-outcome association were causal (Figure 2). 304 
The expected association is calculated by multiplying the observed instrument-305 
exposure association with the observed exposure-outcome association while the 306 
standard error for the expected effect size is calculated using a second order Taylor 307 
series expansion of the product of two means, where the covariance of the estimated 308 
parameters was estimated using a bootstrapping procedure with 200 replications (48).  309 
 310 
Here we estimated the expected effect of the instrument-outcome association based on 311 
the effect estimates for the instrument-exposure and exposure-outcome associations 312 
and compared this with the observed association of instrument with outcome (DNA 313 
methylation), performing a z-test for difference between the observed and expected 314 
estimates, where again the covariance of the estimated parameters was estimated 315 
using a bootstrapping procedure. Where the observed and expected estimates are 316 
consistent this suggests that there is unlikely to be marked residual confounding in the 317 
association between exposure and outcome (i.e. it supports a causal effect); assuming 318 
there is adequate statistical power for this comparison. The only covariate included in 319 




Inter-generational analysis 322 
We next performed multivariable linear regression analysis to investigate associations 323 
between log-transformed maternal pre-pregnancy BMI and offspring HIF3A 324 
methylation at birth, childhood and adolescence. These models adjusted for maternal 325 
age at delivery, maternal smoking status in pregnancy, offspring sex and bisulphite 326 
conversion batch. Analyses assessing the association of maternal BMI with childhood 327 
and adolescent methylation at HIF3A were also adjusted for offspring’s age at 328 
methylation measurement.  329 
 330 
Primarily we were interested in the direction of any causal effect and this inter-331 
generational design effectively rules out an effect of offspring methylation on 332 
maternal BMI. Should any robust associations of maternal BMI with offspring DNA 333 
methylation at HIF3A be identified, we planned to use causal inference strategies to 334 
investigate whether these associations were likely to be caused by an intra-uterine 335 
effect of maternal BMI or rather by confounding due to shared familial lifestyles 336 
and/or genetic factors.   337 
 338 
Specifically, these strategies were a negative control design and Mendelian 339 
randomization. In the negative control design, associations of maternal exposure and 340 
paternal exposure (the negative control) with the offspring outcome are compared. If 341 
these are similar it suggests that confounding by shared familiar factors, shared 342 
epigenetic inheritance or  parental genotypes is likely, whereas a stronger maternal-343 
offspring association (even after adjustment for paternal exposure) would provide 344 
support for a causal intra-uterine effect.( 49; 50) Associations of maternal pre-345 
pregnancy BMI and offspring methylation at HIF3A were therefore compared, 346 
15 
 
visually and formally using incremental F-tests, to associations of paternal BMI and 347 
offspring methylation, with and without mutual adjustment.  348 
 349 
For the Mendelian randomization analysis, genetic variants in the mothers were used 350 
to create a weighted allele score for maternal BMI and the instrumental variable 351 
approach of triangulation was applied to infer a causal effect on offspring DNA 352 
methylation at HIF3A. However, in this case an obvious violation of the instrumental 353 
variable assumption is the relationship of maternal genotype to offspring (fetal) 354 
genotype which could provide a pathway from the instrument (maternal genotype) to 355 
outcome (offspring DNA methylation at HIF3A) that is not via the exposure of 356 
interest (maternal BMI) and hence would bias our findings.(51) Therefore, the 357 
analysis was adjusted for offspring’s BMI allele score. All analyses were also 358 
adjusted for bisulphite conversion batch. 359 
 360 
All statistical analyses were performed in R (version 3.0.1).  361 
 362 
Results  363 
Basic characteristics  364 
Methylation data were available for 973 children at the mean age of age 7.5 (S.D. 0.1) 365 
years and 974 adolescents at the mean age of 17.1 (1.0) years, with 940 individuals 366 
having data at both of these time points. For the three HIF3A probes identified 367 
previously, mean methylation levels were lower in adolescence than in childhood 368 
(Table 1). Methylation in childhood was positively associated with methylation in the 369 
same individuals assessed in adolescence (Pearson’s correlation coefficients: 0.72, 370 
0.57, 0.68 at cg22891070, cg27146050 and cg16672562, respectively). R2 values for 371 
16 
 
regressions of methylation in adolescence on methylation in childhood showed that 372 
childhood methylation explained 52.3%, 32.4% and 46.8% of variation in methylation 373 
in adolescence at cg22891070, cg27146050 and cg16672562 respectively  374 
 375 
Cross-sectional analysis  376 
There were no cross-sectional associations between methylation at cg22891070 and 377 
cg16672562 and BMI in childhood or adolescence (Table 2). There was also no 378 
robust association between methylation at cg27146050 and childhood BMI (Table 2), 379 
although there was some suggestive evidence of association between and methylation 380 
across the HIF3A region and childhood BMI (Supplementary Figure 1). An 381 
association between methylation at cg27146050 and BMI in adolescence withstood 382 
Bonferroni correction; a 0.1 increase in methylation β value at cg27146050 was 383 
associated with a 4.7% (95% CI 1.0, 8.3; P=0.012) increase in BMI, which is in line 384 
with previously reported adult BMI effect estimates.(6)  385 
We investigated whether the observed association between adolescent BMI and 386 
cg27146050 methylation could be explained by additional confounding factors 387 
(Supplementary Table 2). The association between methylation at cg27146050 and 388 
BMI in adolescence was attenuated by 25% upon adjustment for these, indicating 389 
some potential confounding in the observational association (Table 2). DNA was 390 
extracted from buffy coats in adolescence. To establish the effect of correcting for 391 
buffy coat cell type, predicted cell type components were added as covariates to the 392 
main and secondary models. Evidence for association strengthened following this 393 




Effect estimates for associations between adolescent methylation and fat mass index 396 
(FMI) were consistently larger for all three of the CpG sites compared with those for 397 
BMI, particularly at cg27146050, where an increase in methylation β value of 0.1 was 398 
associated with an 11.8% (-0.1, 23.7) increase in FMI (P=0.053), however confidence 399 
intervals were wider and the p-values for the associations did not withstand 400 
Bonferroni correction. We also investigated whether the observed associations could 401 
be explained by additional confounding factors that may exist in the context of 402 
adiposity and methylation by assessing the impact of adjusting for potential 403 
confounders on the observational effect estimates. The association between 404 
methylation at cg27146050 and FMI in adolescence was similarly attenuated by 25%, 405 
indicating some potential confounding in the observational association 406 
(Supplementary Table 4). 407 
 408 
Longitudinal associations 409 
We next investigated the prospective associations between HIF3A methylation at 410 
birth and childhood BMI, between birth weight and childhood HIF3A methylation, 411 
between childhood HIF3A methylation and adolescent BMI and between childhood 412 
BMI and HIF3A methylation in adolescence, with and without adjustment for 413 
adiposity or methylation at the earlier time point (Table 3). We observed positive 414 
associations between birthweight and childhood methylation at all three sites, which 415 
was not attenuated with adjustment for cord blood methylation at birth (P-values 416 
ranging 0.0019 to 0.019). While there was weak evidence of inverse associations 417 
between HIF3A methylation at birth and childhood BMI, these associations were 418 




We also observed a positive association between childhood BMI and cg27146050 421 
methylation in adolescence (0.003 (0.001, 0.005) increase in methylation β value per 422 
10% increase in BMI; P=0.001) which was not attenuated with adjustment for 423 
childhood methylation at this site. The effect remained unchanged with adjustment for 424 
a number of potential confounders (Supplementary Table 5). However, there were 425 
no prospective associations between childhood BMI and adolescent methylation at 426 
cg22890170 or cg16672562  427 
 428 
Mendelian randomization analysis 429 
To investigate the potential effect of methylation at cg27146050 on BMI, we first 430 
assessed genetic associations with methylation using a score composed of two single 431 
nucleotide polymorphisms (SNPs), rs8102595 and rs3826795, found to have strong 432 
cis-effects on methylation at HIF3A in an independent study (6). There was a 0.2 433 
(0.16, 0.25; P<10-10; R2=7.4%) increase in methylation β value at cg27146050 per 434 
unit increase in the cis-SNP score (Supplementary Table 6). Unlike for the adiposity 435 
and methylation measures, there was no strong evidence of association between the 436 
cis-SNP score and a number of potential confounding factors (Supplementary Table 437 
8).  438 
 439 
Given the strength of the association with methylation at cg27146050 and lack of 440 
association with confounding factors, we used the cis-SNP score as an instrument for 441 
methylation in a Mendelian randomization analysis. There was little association 442 
between the cis-SNPs and BMI compared with the expected association if 443 
methylation on BMI was causal (Table 4). However, wide confidence intervals for 444 
the observed estimates meant that there was no strong evidence of a difference 445 
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between the observed and expected effect estimates (observed effect = -0.04 (-0.29, 446 
0.22); expected effect = 0.10 (0.03, 0.17); P-for-difference= 0.30).   447 
 448 
We calculated that we would need a sample of N=25,369 to confidently detect an 449 
association (at p<0.001) between the cis-SNP allele score that explained 0.1% of the 450 
variance in log BMI with 95% power. Therefore, we also tested for associations 451 
between the cis-SNPs and body mass index by performing a look-up of the SNPs in 452 
the publically-available results of the most recent GIANT consortium meta-453 
analysis.(44) In this sample, there was no strong evidence of association between 454 
either of the SNPs and BMI (rs3826795: n=224,403, β (SE) = 0.002 (0.005), p=0·63; 455 
rs8102595: n=223,534, β (SE) = -0.002 (0.007), p=0·78), in accordance with previous 456 
findings using data from a smaller meta-analysis in GIANT. (6) In addition, we 457 
performed two-sample Mendelian randomization,(52) using SNP-methylation 458 
association estimates obtained from the ARIES data set and SNP-BMI association 459 
estimates obtained from the GIANT results to derive a Wald ratio estimate for the 460 
causal effect of methylation on BMI. Using inverse-weighted variance meta-analysis 461 
of the estimates derived using the two SNPs, a 1-unit increase in methylation was 462 
associated with a -0.021 (-0.55, 0.51); p=0.94 decrease in inverse-normally 463 
transformed BMI residuals i.e. providing further evidence against a causal effect of 464 
methylation at HIF3A on BMI  (Supplementary Table 10).  465 
 466 
To investigate the potential effect of BMI on methylation at cg27146050, we 467 
confirmed the expected association between a weighted allele score composed of 97 468 
BMI variants identified in an independent study(44) and log-transformed BMI in our 469 
sample (β =0.036 (0.025, 0.046) P<10-10, R2=5.2%) (Supplementary Table 7). 470 
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Unlike for the adiposity and methylation measures, there was no evidence of 471 
association between the BMI allele score and a number of potential confounding 472 
factors (Supplementary Table 8). Although there was some evidence for a difference 473 
in mean allele score between groups based on adolescent own smoking, this was 474 
driven by a small number of individuals in the group who smoked weekly (n= 29) and 475 
no linear trend was observed.   476 
 477 
We applied this instrument to investigate the potential causal effect of BMI on HIF3A 478 
methylation (Table 4). The direction of effect observed was consistent with that 479 
expected if the effect were causal. In addition, there was little evidence of a difference 480 
between the observed and expected effect estimates (observed effect = 0.0014 (-481 
0.0009, 0.0037); expected effect = 0.0008 (0.0002, 0.0013); P-for-difference=0.55). 482 
However, due to wide confidence intervals, no robust evidence of an association 483 
between the allele score and methylation was observed. In order to confidently detect 484 
an association between the BMI allele score and HIF3A methylation (at p<0.001) that 485 
explained 0.1% of the variance in log BMI with 95% power, we calculated that we 486 
would need a sample of N=30,523. Unfortunately, no publically-available meQTL 487 
data of this sample size are currently available to investigate this.   488 
 489 
Inter-generational analysis  490 
We next carried out an inter-generational analysis to investigate a potential intra-491 
uterine effect of maternal BMI on offspring methylation at cg27146050 from birth to 492 
adolescence. Maternal pre-pregnancy BMI was associated with offspring cord blood 493 
methylation at cg27146050 (P= 0.027). However, whereas own BMI was positively 494 
associated with methylation at this site, maternal BMI was inversely associated with 495 
21 
 
offspring DNA methylation at cg27146050 in cord blood (-0.0048 (-0.0092, 0.0004) 496 
change in methylation per 10% increase in maternal BMI) (Figure 3).  497 
 498 
Maternal BMI was also associated with cord blood methylation at four other CpG 499 
sites at HIF3A (cg20667364, cg26749414, cg25196389 and cg23548163; P-values 500 
ranging 7.5 × 10-6 to 4.6 × 10-2) (Figure 3).  These sites in the second CpG island 501 
were found to be positively associated with maternal BMI (in contrast to cg27146050, 502 
which was negatively associated). A heatmap of the correlation between methylation 503 
β-values at HIF3A (Supplementary Figure 2) shows that the sites in the second CpG 504 
island are inversely correlated with cg27146050.  505 
 506 
Associations between maternal BMI and offspring methylation at birth at the 507 
additional sites in the second CpG island did not persist at later ages (Supplementary 508 
Figure 3, birth n = 795, childhood n = 845, adolescence n = 851). The inverse 509 
association of maternal pre-pregnancy BMI with methylation at cg27146050 in cord 510 
blood reversed to a positive one in adolescence, in line with the association of own 511 
BMI with methylation at this site.  512 
 513 
Using a negative control design, we found that the association between maternal BMI 514 
and offspring methylation at the sites identified in cord blood tended to be stronger 515 
than the association with paternal BMI (Figure 4, maternal n =797, paternal n = 655, 516 
mutually adjusted n = 625), but after mutual adjustment of maternal and paternal 517 
BMI, there was only robust evidence that they differed at cg25196389 (Wald test p-518 
value for difference between maternal and paternal associations with mutual 519 
adjustment: 0.031 for cg25196389, all other probes > 0.05). We also found that, for 520 
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cg27146050 in adolescence, the association with pre-pregnancy maternal BMI was 521 
stronger than the association with paternal BMI with and without mutual adjustment 522 
(Figure 4; Wald test p-value = 0.009), and was also stronger than the association with 523 
maternal BMI measured postnatally when their offspring were approximately age 15 524 
(Figure 4; Wald test p-value = 0.050 in adjusted model).  525 
 526 
In the Mendelian randomization analyses of maternal BMI on cord blood methylation 527 
(Supplementary Table 9), the observed associations between the IV and offspring 528 
methylation were stronger than the expected estimates, though 95% confidence 529 
intervals were wide and included the null value at most sites. There was little 530 
evidence that the expected and observed associations of the maternal BMI allele score 531 
with offspring methylation differed.  Adjusting for offspring allelic score slightly 532 
strengthened the observed maternal allelic score –methylation relationship, but 533 
conclusions were generally the same. However, in the Mendelian randomization 534 
analysis of maternal BMI on cg27146050 methylation in adolescence, there was no 535 
observed association between maternal genotype and offspring methylation which we 536 
would expect to find if the effect of maternal BMI on offspring methylation in 537 
adolescence was causal. However, again effect estimates were imprecise. 538 
(Supplementary Table 9).  539 
 540 
Discussion  541 
In this study, we tested for replication of a previous investigation of the association 542 
between BMI and DNA methylation at HIF3A in childhood and adolescence in a 543 
subset of individuals from the Avon Longitudinal Study of Parents and Children.(6) 544 
Although no clear cross-sectional associations were observed between childhood BMI 545 
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and methylation, we found evidence of a positive association between adolescent 546 
BMI and methylation at cg27146050 in HIF3A, with a magnitude of effect similar to 547 
that seen previously.(6)  548 
 549 
We also examined the association between HIF3A methylation and DXA-derived 550 
FMI in adolescence and found positive associations at all three CpG sites. Effect 551 
estimates were larger than those observed in the associations with BMI, although the 552 
associations were imprecisely estimated with wide confidence intervals that included 553 
the null value.  554 
 555 
We carried out several additional analyses to investigate the dominant direction of 556 
causality in any observed associations (Figure 1). In longitudinal analysis, we found 557 
an association between childhood BMI and methylation in adolescence, but childhood 558 
methylation was not robustly associated with BMI in adolescence, implying that the 559 
direction of any possible effect is from adiposity to methylation at this locus, rather 560 
than the other way round.  561 
 562 
For the Mendelian randomization analysis, we confirmed associations between two 563 
cis-SNPs and methylation at HIF3A and, in line with the aforementioned study, (6) 564 
did not find associations between these SNPs and BMI, suggesting that variation in 565 
methylation at HIF3A does not causally affect BMI. This was supported by our 566 
finding that the observed effect estimate of the SNPs on BMI was different from that 567 
expected if methylation at HIF3A had a causal effect on BMI in the ARIES sample, as 568 
well as a null effect estimate for the causal effect of HIF3A methylation on BMI in 569 
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the GIANT data set (44) established using a two-sample Mendelian randomization 570 
approach.  571 
 572 
We were able to extend the analysis by using instruments for BMI to investigate 573 
causality of the reciprocal effect. We used an allele score composed of variants 574 
robustly associated with BMI in an independent GWAS (44) and assessed the 575 
magnitude of association between this score and methylation at HIF3A in 576 
adolescence. Whilst this analysis showed no robust evidence of an association 577 
between the allele score and methylation, confidence intervals were wide and here the 578 
observed effect estimate was in the same direction and exceeded the expected 579 
magnitude of a causal effect.     580 
Several studies have shown that maternal adiposity during pregnancy is associated 581 
with offspring DNA methylation.(53-56) We carried out inter-generational analysis 582 
and identified associations between maternal pre-pregnancy BMI and offspring cord 583 
blood methylation at cg27146050, as well as four novel CpG sites at HIF3A. Since 584 
the association of maternal BMI with offspring DNA methylation could not be 585 
explained by reverse causality, this lends further plausibility to an effect of adiposity 586 
on DNA methylation at HIF3A. 587 
 588 
Associations of maternal BMI and offspring methylation at the novel sites at HIF3A 589 
were stronger at birth than in childhood and adolescence, suggesting that any effect of 590 
maternal BMI on neonatal DNA methylation at these sites does not persist into later 591 
life.  This seemingly transient effect of maternal BMI on offspring cord methylation 592 
at HIF3A may be indicative of changes in the regulation of HIFs specific to 593 
pregnancy.(57) Meanwhile, for cg27146050, an association between maternal BMI 594 
25 
 
and offspring methylation was evident at all three time points, although the direction 595 
of the association changed over time.   596 
 597 
Some evidence for a causal intra-uterine effect of maternal BMI on offspring cord 598 
blood was supported with the use of both a parental negative control comparison 599 
analysis, where no association was seen between paternal BMI (the negative control) 600 
and offspring cord methylation, and Mendelian randomization using a BMI allele 601 
score in the mothers. For the latter, conclusions were similar even after adjustment for 602 
offspring genotype. A parental comparison analysis also provided support for a 603 
possible legacy from the intra-uterine effect of maternal BMI on offspring DNA 604 
methylation into adolescence, as has been previously identified in the case of maternal 605 
smoking in pregnancy.(58; 59) However, this could be influenced by parental 606 
differences in the proportion of environmental factors shared with offspring 607 
postnatally and, while maternal BMI in pregnancy was more strongly associated with 608 
offspring methylation than maternal BMI postnatally, Mendelian randomization did 609 
not provide strong support for a causal intra-uterine effect at this later time point. 610 
 611 
Strengths of this analysis include the extension of a previous study, with the aim of 612 
replicating identified associations between BMI and methylation at HIF3A locus in a 613 
younger cohort. We obtained similar findings in terms of direction of effect between 614 
BMI and methylation at the identified CpG sites in HIF3A although associations were 615 
weaker, as has been found previously.(9) In addition, more thorough consideration 616 
has been given to a number of potential confounding factors and both longitudinal and 617 
Mendelian randomization analysis have been used to assess causality in the observed 618 




The main limitation of this analysis was the limited power to detect a difference 621 
between the observed and expected triangulation estimates between the BMI allele 622 
score and DNA methylation and further exploration in additional large studies is 623 
warranted. Other possible limitations of Mendelian randomization include population 624 
stratification, canalization, pleiotropy and linkage disequilibrium.(18; 21; 60) Major 625 
population stratification is unlikely since this analysis was completed in unrelated 626 
individuals of European ancestry. However, a pleiotropic association of either a cis-627 
SNP with BMI or the BMI allele score with HIF3A methylation, or linkage 628 
disequilibrium between these genotypes and a functional variant independently 629 
associated with the outcome, would violate the assumptions of the Mendelian 630 
randomization analysis.  631 
 632 
While the genetic variants included in the cis-SNP score were found to be robustly 633 
associated with cg27146050 methylation levels, in a previous study they have been 634 
associated with methylation at the neighbouring CpG, cg22891070, implying non-635 
specificity of these genetic instruments which instead proxy for regional HIF3A 636 
methylation levels rather than methylation at individual CpG sites.  To investigate 637 
specificity of the BMI SNPs, we performed a look-up of the 97 SNPs in a large scale 638 
meQTL analysis within the ARIES data set and did not find any SNP-CpG 639 
associations which surpassed genome-wide significance, indicating that it is unlikely 640 
that the BMI SNPs have a pleiotropic influence on methylation independent of BMI.  641 
 642 
Canalization (or developmental compensation) could potentially bias the Mendelian 643 
randomization analysis assessing causality in the adolescent BMI-methylation 644 
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association but is not an issue in the inter-generational analysis since the mother’s 645 
genetic instrument will only influence the developmental environment of the 646 
offspring through the exposure of interest.(61) Nonetheless, the inter-generational 647 
Mendelian randomization estimates are potentially biased with adjustment for 648 
offspring BMI genotype, which might introduce a different pathway between 649 
maternal BMI genotype and paternal BMI genotype (a form of collider bias). 650 
However, as we have already stated it is unlikely that paternal BMI will have a direct 651 
effect on offspring methylation and adjusting for offspring BMI genotype did not 652 
substantially alter effect estimates for this MR analysis.  653 
Further limitations of the study include missing data for BMI, FMI and some of the 654 
potential confounders which reduced the complete case sample size. It should be 655 
noted that we found no CpG sites in HIF3A that were associated with either offspring 656 
or maternal BMI with a P-value <1 × 10-7 (the widely-used Bonferroni cut-off for 657 
genome-wide significance on the HM450 array), therefore an epigenome-wide 658 
association study of own or maternal BMI in ARIES would not have identified any 659 
sites in HIF3A. However, given the existence of correlation structure and co-660 
methylation in this region, correction for multiple testing based on independent tests 661 
in an EWAS would likely be too stringent. Additionally, eight of the 25 Illumina 450k 662 
probes at HIF3A appear on a comprehensive list of probes that provide noisy or 663 
inaccurate signals.(62) This list includes two (cg22891070 and cg16672562) of the 664 
sites previously identified as being associated with own BMI, so these findings are at 665 
a high risk of being false discoveries. In addition, although not the primary focus of 666 
our analyses, we did not find strong associations between HIF3A methylation at any 667 
of the three sites and BMI in the ARIES mothers at the time of pregnancy or around 668 
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17 years later at follow-up, although the direction of effect was consistent with that 669 
found previously at these sites (6) (Supplementary Table 11). 670 
 671 
An additional limitation is that cord blood or peripheral blood may not be the most 672 
appropriate tissues in which to study associations with BMI and a more pronounced 673 
association of BMI with HIF3A methylation has been observed in adipose tissue.(6; 674 
7). Furthermore, this analysis was limited to blood samples with mixed cell 675 
composition. Although no differences were found in the analysis with estimated cell-676 
type correction, it is unclear how effective the method used to correct for cell-type 677 
proportions is in these samples since the reference data sets are available only for 678 
adult peripheral blood (39).  679 
 680 
Conclusions  681 
Overall our results do not support a causal effect of HIF3A methylation on BMI, and 682 
are more suggestive of a causal effect in the reverse direction i.e. an effect of higher 683 
BMI on higher HIF3A methylation. Use of a range of causal inference techniques 684 
including longitudinal analysis, Mendelian randomization and a parental comparison 685 
design provided findings largely consistent with both a causal effect of own BMI on 686 
methylation at HIF3A as well as an independent intra-uterine effect of maternal BMI 687 
on offspring cord blood methylation at HIF3A (Supplementary Figure 1). Further 688 
work is required to uncover the mechanisms underlying both a direct and intra-uterine 689 
effect of adiposity on DNA methylation in this gene and to investigate its role in the 690 
downstream effects of adiposity, given that methylation changes have been shown to 691 
influence gene expression at this locus.(6) 692 
 693 
  694 
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 1068 
Figure legends 1069 
Figure 1 - Schematic diagrams of the causal inference methods being implemented in 1070 
this study  1071 
a) Investigating longitudinal associations between BMI and HIF3A methylation 1072 
b) Investigating the dominant direction of causality in the association between BMI 1073 
and HIF3A methylation with the use of bidirectional Mendelian randomization 1074 
analysis  1075 
c) Investigating the intra-uterine effect of maternal smoking on offspring DNA 1076 
methylation with the use of a parental comparison design.  1077 
 1078 
Figure 2 - Triangulation approach for instrumental variable analyses used in this 1079 
study 1080 
The observed association between the instrumental variable and the outcome (a) is 1081 
compared to that expected given the association between the instrumental variable 1082 
and the exposure (b) and the association between the exposure and the outcome (c). 1083 
 1084 
Figure 3 – Associations between maternal BMI and offspring methylation at birth at 1085 
HIF3A CpG sites  1086 
Associations of maternal BMI and offspring cord blood methylation at birth at all 25 1087 
CpG sites at the HIF3A locus (mean change in methylation per unit increase in log 1088 
maternal pre-pregnancy BMI; error bars indicate 95% confidence intervals). The 1089 
locations of CpG sites on the HIF3A gene are mapped on the diagram below the 1090 
graph. Blue blocks are exons, grey blocks are introns, green blocks are CpG islands 1091 
and red pins are CpG sites. The three sites previously identified in adult peripheral 1092 
blood as associated with own BMI are highlighted with a red asterisk. All sites 1093 
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associated with maternal BMI with a P-value <0.05 in our analyses are highlighted 1094 
with a blue asterisk. 1095 
 1096 
Figure 4 – Associations between parental BMI and offspring DNA methylation at 1097 
HIF3A 1098 
Error bars indicate 95% confidence intervals. Maternal antenatal n = 849 [birth] 904 1099 
[adolescence], paternal n = 694 [birth] 742 [adolescence], mutually adjusted n =662 1100 
[birth] 708 [adolescence], maternal at follow-up n = 819 [adolescence], maternal 1101 
antenatal adjusted for maternal at follow-up n = 763 [adolescence]. 1102 
 1103 
Tables 
Table 1 – Characteristics of ARIES participants included in analyses 
 ARIES participants* 
 Childhood (N=970) Adolescence (N= 845) 
Age (years)  7.5 (0.1) 17.1 (1.0) 
% males 485 (49.8%) 474 (48.7%) 
Height (m)  1.26 (0.05) 1.72 (0.09) 
Weight (kg) 25.9 (4.6) 66.2 (9.1) 
Body mass index (kg/m2) 16.2 (2.1) 22.3 (3.9) 
Fat mass index (kg/m2) - 5.9 (3.5) 
% fat mass - 25.1% (11.0%) 
% smoke at least weekly  - 130 (15.2%) 
Methylation of cg22891070 (β value) 0.664 (0.102, 0.281-0.918) 0.578 (0.120, 0.200-0.884) 
Methylation of cg27146050 (β value) 0.182 (0.035, 0.080-0.538) 0.167 (0.033, 0.083-0.399) 
Methylation of cg16672562 (β value) 0.660 (0.131, 0.200-0.930) 0.536 (0.147, 0.122-0.925) 
*Data are mean (SD), n (%), or mean (SD, range) 
 
 
Table 2 – Associations between methylation at three CpG sites at HIF3A and BMI  
 
 Childhood  Adolescence  
 Basic model (N=970)* Adjusted model (N=918)† Basic model (N=845)‡ Adjusted model (N=804)† 
 Percentage change 
in BMI (95% CI)§ 
p-value Percentage change 
in BMI (95% CI)§ 
p-value Percentage change 
in BMI (95% CI)§ 
p-value Percentage change 
in BMI (95% CI)§ 
p-value 
cg22891070 0.44 (-0.35, 1.23) 0.27 0.45 (-0.32, 0.12) 0.25 0.66 (-0.31, 1.63) 0.19 0.30 (-0.67, 1.28) 0.54 
cg27146050 0.62 (-1.69, 2.93) 0.60 0.34 (-1.89, 2.56) 0.77 4.66 (1.04, 8.29) 0.01 3.49 (-0.12, 7.10) 0.06 
cg16672562 0.31 (-0.32, 0.93) 0.34 0.32 (-0.29, 0.93) 0.30 0.40 (-0.41, 1.20) 0.34 0.24 (-0.56, 1.05) 0.55 
*Childhood analyses are adjusted for age, sex and batch. 
‡ Adolescent analyses are adjusted for age, sex, smoking and batch. 
† Basic model additionally adjusted for smoking, alcohol, maternal education, social class, maternal smoking, maternal smoking, maternal alcohol, birthweight 
and gestational age.  









Table 3 - Prospective associations between birthweight and childhood methylation, between cord blood methylation at birth and childhood BMI, between 
childhood BMI and adolescent methylation, and between childhood methylation and adolescent BMI   
Exposure Outcome CpG site N Association without adjustment 
for the outcome at baseline*  
N Association with adjustment for the 
outcome at baseline*  
    β (95% CI) p-value   β (95% CI) p-value 
Birth methylation Childhood BMI cg22891070 890 -1.70 (-3.66, 0.30)a 0.10 874 -1.65 (-3.52, 0.26)a 0.09 
  cg27146050 890 -0.03 (-1.04, 1.00)a 0.96 874 0.21 (-0.77, 1.21)a 0.67 
  cg16672562 890 -2.66 (-5.10, -0.16)a 0.04 874 -2.23 (-4.58, 0.17)a 0.07 
Birth weight Childhood  methylation cg22891070 957 0.02 (0.01, 0.04)b 0.01 871 0.02 (0.003, 0.035)b 0.02 
  cg27146050 957 0.01 (0.001, 0.012)b 0.02 871 0.01 (0.003, 0.014)b 0.04 
  cg16672562 957 0.03 (0.01, 0.05)b 0.01 871 0.03 (0.006, 0.046)b 0.01 
Childhood methylation Adolescent BMI  cg22891070 922 0.68 (-0.40, 1.76)a 0.22 919 0.14 (-0.64, 0.91)a 0.73 
  cg27146050 922 2.30 (-0.83, 5.43)a 0.15 919 1.33 (-0.91, 3.57)a 0.24 
  cg16672562 922 0.31 (-0.54, 1.15)a 0.48 919 -0.04 (-0.64, 0.57)a 0.90 
Childhood BMI  Adolescent methylation cg22891070 971 0.005(-0.002, 0.011)c 0.17 937 0.001 (-0.004, 0.005)c 0.78 
  cg27146050 971 0.003 (0.001, 0.005)c 0.001 937 0.003 (0.001, 0.004)c 0.001 
  cg16672562 971 0.005 (-0.003, 0.013)c 0.21 937 0.002 (-0.004, 0.008)c 0.60 
*Also adjusted for age at childhood/adolescence, sex, batch  
a Coefficients have been converted into percentage change in BMI for every 0.1 unit increase in methylation β value. 
bCoefficients are change in methylation per 1kg increase in birthweight.  












Exposure (E) Outcome (O) Observed association between IV and O 
(c)* 
Expected association 
between IV and O (a x b) 
Difference between 
observed (c) and 
expected (a x b) 
estimates 






Adolescent log BMI 831 -0.0381 (-0.2937, 0.2176) 0.1027 (0.0315, 0.1739) 0.30 
Adolescent 
standardised 97 






849 0.0014 (-0.0009, 0.0037) 0.0008 (0.0002, 0.0013) 0.55 
*Analyses are adjusted for bisulphite conversion batch only 
 






























a) Longitudinal associations b) Bidirectional Mendelian randomization 







Exposure (E) Outcome (O)
Observed association 
between IV and E
Observed association 
between IV and O
Observed association 































Maternal BMI adjusted for paternal BMI
Paternal BMI
Paternal BMI adjusted for maternal BMI




Change in methylation per 10% increase in mother's BMI
l Pre−pregnancy BMI Follow−up BMI Follow−up BMI adjusted for pre−pregnancy BMI
Offspring DNA methylation at adolescence
















































and lifestyle factors 
          
HIF3A with causal 
effect on BMI 
          
BMI with causal 
effect on HIF3A 
          
Bidirectional causal 
effect 
          




          
Unfilled boxes represent no associations observed in the outlined analyses, dark filled boxes represent strong evidence of association and light 
filled boxes represent weak evidence of association. 
Supplementary Table 2 - Associations between methylation at cg27146050 in adolescence and potential confounding factors  
Confounder Group Methylation at cg27146050 (N=974) † 
  Mean P-value for trend 
Adolescent age <17 years  0.172 
0.006 
 ≥17 years  0.165 
Sex Male  0.171 
<0.001 
 Female  0.162 
Birthweight  Low  0.168 
0.001  Normal  0.165 
 Macrosomia  0.176 
Gestational age Pre-term  0.165 
0.88  Term  0.167 
 Post-term  0.162 
Maternal education  No degree  0.168 
0.08 
 Degree  0.163 
Household social class Manual  0.170  
0.22  Not manual  0.166 
Adolescent  
smoking status 
Never/less than weekly  0.167 
0.77 Weekly  0.171 
Daily  0.166 
Adolescent alcohol 
consumption  
Less than weekly  0.166 
0.79 
At least weekly  0.167 
Maternal smoking 
during pregnancy 




during first trimester 
Never  0.168  
0.28 Any 0.166 
†N varies from 792 to 974 depending on completeness of data. 
Supplementary Table 3 – Associations between methylation at cg27146050 and BMI in adolescence with adjustment for cell composition  
  Without adjustment for cell 
composition 
With adjustment for cell 
composition 
Model N Percentage change 
in BMI (95% CI) c 
p-value Percentage change 
in BMI (95% CI) c 
p-value 
Basic modela 845 4.66 (1.04, 8.29) 0.012 5.27 (1.62, 8.92) 0.005 




a adjusted for age, sex, smoking and batch  
b adjusted for age, sex, smoking, batch, alcohol, maternal education, social class, maternal smoking, maternal alcohol, birthweight and 
gestational age 
c Coefficients have been converted into percentage change in BMI for every 0.1 unit increase in methylation β value. 
 
 
Supplementary Table 4- Associations between methylation at three CpG sites at HIF3A and FMI in adolescence 
 Basic model (N=829) a Adjusted model (N=789) b 
 Percentage change 
in BMI (95% CI)c 
p-value Percentage change 
in BMI (95% CI)c 
p-value 
cg22890170 2.84 (-0.37, 6.05) 0.08 1.99 (-1.28, 5.25) 0.23 
cg27146050 11.79 (-0.15, 23.72) 0.05 8.86 (-3.27, 20.98) 0.15 
cg16672562 1.87 (-0.77, 4.52) 0.17 1.55 (-1.16, 4.26) 0.26 
 
a Adjusted for age, sex, smoking and batch. 
b Basic model additionally adjusted for smoking, alcohol, maternal education, social class, maternal smoking, maternal smoking, maternal 
alcohol, birthweight and gestational age.  






Supplementary Table 5  - Prospective associations between childhood BMI and adolescent methylation, and between childhood methylation and 
adolescent BMI, adjusted for potential confounding factors  
 
Exposure Outcome CpG site N Association without adjustment for 
the outcome at baseline * 
N Association with adjustment 
for the outcome at baseline * 
    β (95% CI) p-value   β (95% CI) p-value 
Birth methylation Childhood BMI cg22891070 825 -1.74 (-3.69, 0.25)a 0.09 814 -1.54 (-3.46, 0.43)a 0.09 
  cg27146050 825 -0.06 (-1.10, 0.99)a 0.91 814 0.22 (-0.82, 1.27)a 0.67 
  cg16672562 825 -2.54 (-4.95, -0.06)a 0.04 814 -2.50 (-4.87, -
0.07)a 
0.07 
Birth weight Childhood 
methylation 
cg22891070 892 0.02 (0.003, 0.04)b 0.02 811 0.02 (0.001, 
0.034)b 
0.02 
  cg27146050 892 0.01 (0.0003, 0.01)b 0.04 811 0.01 (0.002, 
0.013)b 
0.04 





Adolescent BMI  cg22891070 872 0.53 (-0.55, 1.60) a 0.34 869 0.03 (-0.82, 0.77) a 0.95 
  cg27146050 872 1.60 (-1.47, 4.68) a 0.31 869 0.78 (-1.50, 3.06) a 0.50 
  cg16672562 872 0.16 (-0.68, 1.00) a 0.70 869 -0.21 (-0.83, 0.42) 
a 
0.51 
Childhood BMI  Adolescent 
methylation 
cg22891070 919 0.005 (-0.002, 0.013) 
c 
0.15 886 0.001 (-0.005, 
0.006) c  
0.83 
  cg27146050 919 0.003 (0.001, 0.005) c  0.001 886 0.003 (0.001, 
0.004) c  
0.001 
  cg16672562 919 0.007 (-0.002, 0.016) 
c  
0.12 886 0.003 (-0.004, 
0.009) c 
0.39 
*Also adjusted for age in childhood/adolescence, sex, batch, maternal education, social class, maternal smoking, maternal alcohol, birthweight 
and gestational age  
a Coefficients have been converted into percentage change in BMI for every 0.1 unit increase in methylation β value. 
bCoefficients are change in methylation per 1kg increase in birthweight.  
c Coefficients are change in methylation per 10% increase in BMI. 
Supplementary Table 6 - Association between SNPs at the HIF3A locus and methylation level at cg27146050 in adolescence 
 
Exposure N Frequency of 
effect allele a 
b (95% CI) p-value R2 c F-statistic 
rs8102595 849 0.099 0.023 (0.018, 0.028)b <10-10 8.0% 73.4 
rs3826795 849 0.780 0.007 (0.003, 0.011)b 0.001 
 
1.4% 12.0 
cis SNP score† 849 - 0.204 (0.155, 0.252) <10-10 7.4% 67.6 
 
These models were adjusted for batch, except when calculating R2 where no covariates were included. 
a Effect allele for rs8102595 is G; effect allele for rs3826795 is C. 
b Coefficients are from an additive model and are a unit change in methylation per copy of the effect allele 
cR2 is the percentage of variation in methylation that is explained by each SNP. 
† cis SNP score = 0.075 x rs8102595 + 0.047 x rs3826795 (using weights from a meta-analysis of the discovery and replication cohorts in Dick 
et al (6).   
 
 
Supplementary Table 7  – Associations between BMI allele scores and BMI in adolescence 
 
 Mean allele 
score (s.d.) 
b (95% CI)a p-value R2 b F-statistic N 
Adolescent 
standardised 97 
SNP allele score 
88.7 (6.2)c 0.036 (0.025, 
0.046) 
<10-10 5.2% 45.7 831 
aCoefficients are change in log(BMI) per unit increase in the standardised allele score. 
bR2 is the percentage of variation in methylation that is explained by the allele score. 
cBMI allele scores are always standardised except when reporting the mean and s.d. of the allele score. 
 
 
Supplementary Table 8 - Associations between body mass index, fat mass index, and genetic variants and possible confounding factors† 








 Mean P-value for  
difference 
Mean P-value for  
difference 
Mean P-value for  
difference 












≥17 years  22.5 5.87 0.089 0.00 







0.24 Female  22.5 7.50 0.087 -0.04 







0.20 Normal  22.2 5.84 0.086 -0.02 
High  23.6 6.28 0.093 0.09 







0.83 Term  22.3 5.90 0.088 0.00 
Post-term  23.6 7.10 0.074 0.20 








































0.04 Weekly  22.9 6.45 0.090 0.45 























Never  22.2  5.75  0.088  -0.02  
Maternal smoking 
during pregnancy 
















Any  22.2 5.68 0.088 0.03 

















Supplementary Table 9 – Mendelian randomization analysis for the association between maternal BMI and offspring methylation at HIF3A.  
Instrumental 
variable (IV) 
Exposure (E) Outcome (O) 
Observed association between IV 
and O (c) 
Expected association 





(a x b) 
estimates 
   N β (95% CI) β (95% CI) P-value 
Maternal 
standardised 97 




Methylation at birth at 
cg27146050 
624 -0.0039 (-0.0118, 0.0039) -0.0011 (-0.0023, 0.0002) 0.46 
Maternal 
standardised 97 




Methylation at birth at 
cg25196389 
624 0.0132 (0.0002, 0.0263) 0.0029 (0.0005, 0.0054) 0.11 
Maternal 
standardised 97 




Methylation at birth at 
cg23548163 
624 0.0025 (-0.0074, 0.0124) 0.0015 (0.0000, 0.0030) 0.84 
Maternal 
standardised 97 




Methylation at birth at 
cg26749414 
624 0.0095 (-0.0110, 0.0301) 0.0064 (0.0022, 0.0105) 0.75 
Maternal 
standardised 97 




Methylation at birth at 
cg20667364 
624 0.0018 (-0.0051, 0.0087) 0.0008 (-0.0003, 0.0019) 0.77 
Maternal 
standardised 97 










-0.0013 (-0.0042, 0.0015) 
 
0.0007 (0.0002, 0.0013) 
 
0.16 
       
 * Analyses adjusted for offspring allele score. 
 
 








Direct-genotype associations Wald-ratio estimate* 
   N β (SE) β (95% CI) 
rs382679 C 0.78 224,403 0.002 (0.005) 0.33 (-1.03, 1.69) 




- - - - -0.02 (-0.55, 0.51) 
*Estimates for SNP-methylation association taken from ARIES; estimates for SNP-BMI association taken from GIANT meta-analysis results of 










Supplementary Table 11 - Associations between methylation at three CpG sites at HIF3A and BMI in adult women 
 
 At pregnancy (mean age 29.2 years) At follow up (mean age 47.4 years)  
 Basic model (N=874)*  Basic model (N=694) * 
 Percentage change 
in BMI (95% CI) 
p-value  Percentage change in 
BMI (95% CI) 
p-value 
cg22891070 0.79 (-0.04, 1.61) 0.06  0.87 (-0.27, 2.02) 0.14 
cg27146050 2.17 (-1.26, 5.71) 0.22  2.85 (-1.84, 7.76) 0.24 
cg16672562 0.75 (0.03, 1.47) 0.04  0.21 (-0.78, 1.21) 0.68 
*Adjusted for age, smoking and batch. 












Supplementary Figure 1 - Associations between methylation at HIF3A CpG sites and BMI 
 
Associations of BMI and peripheral blood methylation at all 25 CpG sites at the HIF3A locus 
in childhood and adolescence. The locations of CpG sites on the HIF3A gene are mapped on 
the diagram below the graph. Blue blocks are exons, grey blocks are introns, green blocks are 
CpG islands and red pins are CpG sites. The three sites previously identified in adult 
peripheral blood as associated with own BMI are highlighted with a red asterisk. No other 
sites survived correction for multiple testing.  
Supplementary Figure 2 - A heatmap of the correlation between methylation β-values at each 
HIF3A CpG site at birth.
 
The locations of CpG sites on the HIF3A gene are mapped on the diagram below the graph. 
Blue blocks are exons, grey blocks are introns, green blocks are CpG islands and red pins are 
CpG sites. The three sites previously identified in adult peripheral blood as associated with 











Supplementary Figure 3 –Associations between maternal pre-pregnancy BMI and offspring 
DNA methylation from birth to adolescence* 
 
 
*birth (cord blood at birth, n=797), childhood (peripheral blood at around 7 years-old, n=846) 
and adolescence (peripheral blood at around 17 years-old, n=853)  
Mean change in methylation 10% increase in maternal pre-pregnancy BMI; error bands 
indicate 95% confidence intervals 
 
